About: Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.36 (-4.23%)
BMEA NASDAQ Biomea Fusion Inc
Biomea Fusion Inc share price
BMEA price activity
Last Price
$1.370
Change (24hr)
-0.06 USD (-3.87%)
Volume
625.60K
Volume (4w avg)
-
Open
$1.44
Day Range
$1.37 - $1.44
Previous Close
$1.42
Last Trade
12 Oct, 7:41 pm GMT+0
Delayed
12 Oct, 7:41 pm GMT+0
BMEA price performance
Delayed
12 Oct, 7:41 pm GMT+0
BMEA Market Signals